Study of the clinical effect of GLP-1 analogue for body weight, body fat, insulin secretion in patients with type 2 diabetes

Study of the clinical effect of GLP-1 analogue for body weight, body fat, insulin secretion in patients with type 2 diabetes - Study of the clinical effect of GLP-1 analogue for body weight, body fat, insulin secretion in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009638

Enrollment

130

Registered

2012-12-26

Start date

2011-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

liraglutide 0.3-0.9mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c (JDS):more than 5.8% Type 2 diabetes Pts with written IC

Exclusion criteria

Exclusion criteria: 1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)pregnacy 4)Allergy for sitagliptin, nateglinide,liraglutide and exenatide 5)Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
change of HbA1c	—

Countries

Japan

Contacts

Public ContactWakana Miura

Department of Internal Medicine, Tokai University School of Medicine Division of Nephrology, Endocrinology and Metabolism

happy0897@gmail.com0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026